Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
Search
Search results
Slowing sight loss in stargardts: Ocugen’s gene therapy trial offers promising early results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Research opportunity for people with confirmed Stargardt disease
Please find below a research opportunity for people with confirmed stargardt disease.
Meet a researcher: Hassina Zeriri
It’s not very often that we come across a researcher working on a project inspired by their own lived experience of a sight loss condition.
SB-007 update: dose-expansion portion of SpliceBio’s phase 1/2 trial underway with first participant dosed at Oxford
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
Clinical Trial Opportunity for Adults with Stargardt Disease
The clinical trial team at The Retina Clinic London have asked us to share an opportunity to participate in a Phase 1 clinical trial for AAVB 039 for Stargardt Disease.
AAVantgarde Completes Enrolment in Phase 1/2 Clinical Trial for Usher Syndrome Type B
The latest research news piece from Retina UK.
RTx-015: Exploring Optogenetic Gene Therapy for RP and Choroideremia
Ray Therapeutics, a clinical stage biopharmaceutical company, is currently investigating their lead optogenetic therapy candidate, RTx-015, in early stage clinical trials for those with RP and Choroideremia.
Our Partners
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.